OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Memorial Sloan Kettering Cancer Center, Seoul National University Hospital, Gdańsk Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, University of Pennsylvania, Osaka National Hospital, Institut Gustave Roussy, First Hospital of Jilin University, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, The Christie Hospital, The Christie NHS Foundation Trust, AstraZeneca (United Kingdom), University of Padua, Istituto Oncologico Veneto
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4252741150